Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERTIL-01: Perkileucel in Advanced Melanoma
NCT07651618Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Jul 2029
- Countries
- 1
- Drugs
- perkileucel
- Conditions
- melanoma
01
Overview
Phase 2, open-label, single-arm trial of perkileucel in melanoma, sponsored by East Metropolitan Health Service. Primary endpoint: Objective Response Rate at 6 months. Planned start Jul 2026; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
TIL-ACT
Perkileucel + Lymphodepletion + IL-2
03
Who it enrols
Adults 18-70 with unresectable stage III or metastatic melanoma, ECOG 0-1, progressed on prior anti-PD1 therapy, with at least 1 surgically accessible lesion >= 1.5 cm.
04
Endpoints
Primary
Objective Response Rate
Secondary
Progression-Free Survival
Overall Survival
Safety Analysis
Beyond the preview
Go deeper on NCT07651618.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07651618.